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Background. Elderly women with breast cancer are considered underdiagnosed and undertreated, and
this adversely affects their overall survival. Between January 2009 and December 2010, 143 patients were
admitted and treated for breast cancer at the Azienda Ospedaliera “S. Maria” Terni-Italy. The patients
were divided into three groups: 70e74, 75e79, and 80 years and older. Results. Lumpectomy was
performed in 42% of all patients, while mastectomy was done in 46% of patients. Adjuvant therapy such
as chemotherapy, radiation therapy, and hormonal therapy were done in 12%, 25%, and 38%, respectively.
Forty-seven percent of patients with positive lymph nodes received chemotherapy. Eighty-six percent of
patients who were estrogen receptor-positive received adjuvant hormonal therapy. Overall ﬁve-year
survival was only 14% for the 80 age group, compared to that of 32% and 35% for the 70e74 and the
75e79 age groups, respectively. Conclusions. Surgery was performed in majority of these patients, about
half received lumpectomy, the other half mastectomy. Adjuvant therapies were frequently excluded, with
only hormonal therapy being the most commonly used. Overall ﬁve-year survival is signiﬁcantly worse
in patients 80 years with breast cancer.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Breast cancer remains the most common cause of death for
women inWestern countries. Interestingly, as with the aging of the
population will have a proportional increase in the number of pa-
tients diagnosed with breast cancer. The increasing age, therefore,
remains the greatest risk factor for the development of the disease.
Numerous studies have shown that 45% of patients with breast
cancer are older than 65 years of age and about 35% are older than
70 years [1,2]. Despite this information, even today, there is a large
number of elderly patients who do not receive adequate treatment
compared to the standard of their younger colleagues [3,4]. This is
due to the fact that with age not only increases the incidence of







by Elsevier Ltd. All rights reserved[5,6]. It is precisely these latter which may signiﬁcantly inﬂuence
the treatment options in the majority of patients. However, a
number of studies have cited that age alone was a determining
factor for the type of treatment of a patient with breast cancer
would receive [7,8]. These studies collectively demonstrate that
elderly patients with breast cancer are more likely to be under-
treated compared to younger patients [9,10]. At present, there is no
consensus on what the best treatment for older patients. This is
partly because patients with breast cancer older are not very well
represented in clinical trials, and in part because there are no
universally accepted guidelines that include not only the cancer-
speciﬁc survival, but also functional status and the patient and
his family preferences [11]. In terms of life expectancy, data from
international statistics have shown that women at age 70 have an
average life expectancy of 15 years, they are relatively healthy and 7
years for those over 85 years. It is thus, that the care of an elderly
patient with breast cancer is very complicated; the treatment of an
elderly patient should be multidisciplinary, possibly requiring the
expertise of a doctor, a geriatrician, a psychiatrist, a surgeon, a
medical oncologist and a radiation oncologist [12]. The use of
screening, also, is very controversial in the elderly population;
However, this, mammography is used in 70% of cases as an adjunct.
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only in 35% of cases for those aged over eighty years. We wanted to
assess whether the treatment and screening for breast cancer of the
elderly in our reality; because considered the growing number of
older women with breast cancer, it is critical to improve the stan-
dard of treatment and surveillance.
2. Material and methods
We analyzed data on 143 elderly patients treated for breast
cancer at the Hospital of Terni from January 2009 to December
2010. The patients were then divided into three age subgroups:
70e74, 75e79 and 80, roughly corresponding to the age cate-
gories used in the deﬁnition of the geriatric population: the young
old (often 65e74 years), the central older (75e85 years), and the
very oldest old (95 years). For each subgroup were collected the
following information: size, grade, histological type of the tumor,
complete staging, estrogen receptor status, type of surgical proce-
dure done, given the type of adjuvant therapy, and survival at 5
years after diagnosis. To compare the characteristics of patients and
the type of treatment adopted in the three groups was used the
Pearson Chi Square test. A value of P 0.05 was considered as
signiﬁcant.
3. Results
We considered 143 female patients (aged 70 years) treated for
breast cancer at the Hospital of Terni from January 2009 to
December 2010, whichwere divided into three different subgroups.
There were 56 patients (39%) in the 70e74 years old group, 41
patients (29%) in the 75e79 year old group, and 46 patients (32%) in
>80 year old group. Majority of our population of patients were
Caucasian white women of all ages (60%), followed by women of
Asian and colored race (40%). From the data in our possession it was
not possible to assess whether the patients were presented with a
palpable lump in the breast or if you had come to the hospital with
radiographic diagnosis of breast cancer. It has been possible to as-
sume that almost all of the patients had reached the observation of
health with swellings more or less palpable since there was no
signiﬁcant difference in tumor size for all age groups (the average
size was 25 mm) and only 7% of all patients had tumors with sizes
less than 10 mm (non-palpable). In forty-nine percent of patients
were diagnosed with stage II disease, in thirteen percent were
diagnosed with stage IV disease in 30 percent have been diagnosed
with third stage disease, and only in eight percent was diagnosed
with stage I disease. Complete staging was performed in seventy-
ﬁve percent of patients. It has not performed in patients older
than 80 years, but this was not statistically signiﬁcant (P  0.20).
The ﬁfty-ﬁve percent of tumors expressed estrogen receptors,
however, in about thirty-seven percent of the 143 tumors it has not
searched for estrogen receptors; similarly, only in forty-seven
percent of the tumor was known positivity for progesterone re-
ceptors, and was unknown in ﬁfty three percent of cases. The sur-
gery was not performed in the eleven percent of patients (P  1),
the breast-conserving surgery (lumpectomy) was performed in
approximately ﬁfty percent of all patients, while the mastectomy
has been performed in twenty-nine percent of patients. Among
patients who did not undergo surgery, eight percent was not a
candidate for any type of surgery, and three percent had declined
the surgical procedure. Adjuvant therapies such as chemotherapy,
radiotherapy and hormone therapy were made in seventy-ﬁve
percent of cases, respectively thirteen percent in the group 70e74
years old, twenty-six percent in the 75e80 group and thirty-six
percent in the group above 80 years. The use of chemotherapy
has been observed to have no signiﬁcant difference in three agegroups. The same observation was noted for radiotherapy and
hormone with values of p  0.10 and 1, respectively. However,
data of survival ﬁve years after diagnosis showed a signiﬁcant dif-
ference between the age groups 75e79 and80 (p 0.001), as well
as that of the 70e74 and 80 age groups (p  0.001). Overall sur-
vival at ﬁve years was only fourteen percent for the age group of
80, compared to that of the thirty-two percent and thirty-ﬁve
percent for the 75e79 and 70e74 age groups, respectively. No
signiﬁcant difference was observed between the 70e74 and 75e79
age groups in terms of survival at ﬁve years (P  1). For patients
who have undergone mastectomy, there was noted a trend of of-
fering an adjuvant to the youngest cohort (70e74 versus  80
years). However, the difference was not statistically signiﬁcant
(P  0.20). Chemotherapy and radiotherapy were given more to
younger patients. That hormone therapy has been noted to be the
same. For those patients who have undergone partial mastectomy
the opposite trend was observed. Patients who were older was
given adjuvant treatment more than the younger age group,
although again, the difference did not have statistical signiﬁcance.
Of note is that there were patients undergoing chemotherapy in
those who had lumpectomy in the age group 70e74, while about
twenty percent received such therapy in the 80 and older group
(P  0.01). The results showed that the forty-seven percent of the
patients found to have positive nodes have received some form of
chemotherapy with either a single agent or multiple agents.
Approximately ﬁfty-ﬁve percent of patients in the age group 70e74
years received chemotherapy compared to only thirty-ﬁve percent
in those aged 80 years and more. However, this difference was not
signiﬁcant (P < 1). There were 42 patients with positive margins of
resection. Of these, 35 (87%) received radiation therapy. However,
there was a signiﬁcant difference in the number of patients who
receive radiation therapy in 70e74 compared with that in the age
group 80 (P  0.025). In patients with hormone receptor positive
status, the eighty-four percent received hormonal therapy in the
age group 70e74 and about ninety percent in the age group 80.
4. Discussion
With the continuous advances in the ﬁeld of health care, pa-
tients are living longer, moving the largest group of assistance to
elderly populations [3,4]. In the ﬁeld of oncology in particular,
about 66% of cases of newly diagnosed breast cancer occur in
women over the age of 60 years. However, even if the new subset of
patients with a diagnosis of breast cancer continues to average
equal to or greater than 65, most of the current search is only
available to the younger population. Advanced age per se has been
considered a risk factor for surgical under-treatment, although
older women tolerate well the breast surgery. Various studies have
shown that age is an important determinant of treatment regard-
less of comorbidities, and disease status. The advances in anes-
thesiology now allows procedures appropriate for almost every
woman who requires a breast surgery. Previous studies have sug-
gested that age was the strongest predictor of minor treatment and
that was what we tried to validate the study. Our evaluations show
that there are observable differences in the various measured pa-
rameters between subgroups and that there is a tendency for the
elderly cohort “undertreated” compared to younger cohorts, but
most of these observations were not considered statistically sig-
niﬁcant. Signiﬁcant differences were noted between the group of
80 and older in age and the age groups 70e74 and 75e79. However,
even if not age alone in this case is the strongest predictor for
survival cannot be fully determined. Beyond the age, perhaps the
results also imply that survival is inﬂuenced by other parameters in
addition to the tumor and patient characteristics identiﬁed in the
study and perhaps functional status and comorbidities play a role.
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the elderly is the concept of life expectancy and considerations of
their families [13e15]. It is true that breast cancer increases with
age [16]. It is, therefore, important to consider the patient's func-
tional status and comorbidity in determining the maximum ben-
eﬁts treatment for patients. It has been shown, for example, in
cancer patients that poor functional status correlates with worse
outcomes regardless of the type of cancer age. At the same time,
with increasing age, the risk of death causes in addition to breast
cancer increases. In explaining the beneﬁts and risks of treatment,
therefore, breast cancer-speciﬁc prognosis, breast-cancer-speciﬁc
prognosis and treatment-related toxicity should be accounted for.
If the assumption then, that perhaps the functional status and co-
morbidity contributed largely to the difference in survival cannot
be determined because not entirely available from the data
collected. Surgery is still the mainstay of treatment for patients
with early stage cancer. It was shown that the breast conservation
surgery that involves partial mastectomy with or without subse-
quent axillary dissection, followed by radiation, has equal efﬁcacy
to wider surgical possibilities as mastectomy. However, the current
data suggest that older women are less likely to be offered breast
conservation surgery than their younger ones [17,18]. The data of
our study show that in this institution, mastectomy and lumpec-
tomy were performed with almost the same frequency, even if the
adjuvant therapy was omitted in most cases. Staging was done for
themajority of patients (75%). Therewas no difference between age
groups (P < 0.20) although younger patients have been organized
more than 80 years old and older cohort. Again, if this was due to
age alone cannot be determined. Yet regardless of age, inﬁltrating
ductal carcinoma is the most common histologic subtype, as
demonstrated in our study as well. Older patients were noted to
have a higher frequency of tumors with more indolent histology
and generally more favorable biological proﬁle of the tumor. Older
women are likely to express estrogen and progesterone receptors,
which improves the prognosis. This will candidate the patients for
adjuvant and hormonal therapy too [19,20]. In our study, the ma-
jority of patients with hormone receptor status Positive received
hormone therapy. As suggested by previous studies, treatments
that offer less toxicity are offered to patients with advanced age.
Hormone therapy that involves less risk and toxicity compared
with chemotherapy is more likely to be offered and given to elderly
patients with breast cancer. Regarding the chemotherapy, the most
commonly used cytotoxic drugs in this environment as cyclo-
phosphamide, methotrexate and 5-ﬂuorouracil are the second line
of systemic therapeutic agents available for women with breast
cancer [17]. Our data have shown that chemotherapy was not
generally offered to our study cohort, and although there was no
statistical difference, there was noted a tendency to give less
chemotherapy as a patient gets older. This can be caused by prob-
lems of toxicity of these agents as well as suggestions below ad-
vantageously as presented in the previous rounds. Radiation
therapy is well tolerated in the elderly. It reduces the ipsilateral
breast cancer recurrence after breast conservation surgery and
chest wall recurrence after a mastectomy. Our study showed that in
patients 80 years and older, radiotherapywas given less than that in
the 70e74 age cohort, which is reasonable given that it is reason-
able to numerous data simply show a decrease in local recurrence
but in the end did not have effect on survival. Previous studies show
that, despite the reduction in the risk of local (from 7.7 to 0.6%,
p < 0.001) and axillary (2.5e0.5%, P < 0.49) recurrence, there is no
signiﬁcant difference in survival [21,22]. The study by Ragaz et al.
[23] shows the same trend of decreased loco regional recurrence,
but no advantage in reducing distant metastases or improve sur-
vival. It may be reasonable, therefore, in elder population [24e26],
to provide radiation therapy to patients who can beneﬁt most asthose with a life expectancy of more than 5 years, those with large
tumors, positive lymph nodes or negative hormone receptors.
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